{"prompt": "['80', 'MC1488 WEE1', 'MCCC', 'Appendix IV: Revised International Prognostic Scoring System (IPSS-R) for MDS', 'IPSS-R Cytogenetic risk groups*,**', 'Cytogenetic prognostic', 'Cytogenetic abnormalities', 'subgroups', 'Very good', '-Y, del(11q)', 'Good', 'Normal, del(5q), del(12p), del(20q), double including del(5q)', 'Intermediate', 'del(7q), +8, +19, i(17q), any other single or double independent clones', 'Poor', '-7, inv(3)/t(3q)/del(3q), double including -7/del(7q), Complex: 3', 'abnormalities', 'Very poor', 'Complex: >3 abnormalities', 'IPSS-R Prognostic Score Values*', 'Prognostic variable', '0', '0.5', '1', '1.5', '2', '3', '4', 'Cytogenetics', 'Very', 'Good', 'Intermediate', 'Poor', 'Very', 'Good', 'Poor', 'BM Blast %', '<=2', '>2-<5%', '5-10%', '>10%', 'Hemoglobin', '=>10', '8-<10', '<8', 'Platelets', '=>100', '50-<100', '<50', 'ANC', '>0.8', '<0.8', 'IPSS-R Prognostic Risk Categories/Scores*', 'RISK CATEGORY', 'RISK SCORE', 'Very Low', '<=1.5', 'Low', '>1.5 3', 'Intermediate', '>3 - 4.5', 'High', '>4.5 - 6', 'Very High', '>6', '* *Greenberg, Tuechler, Schanz et al, Revised International Prognostic Scoring System (IPSS-R) for', 'Myelodysplastic Syndrome, Blood 120: 2454, 2012.', '**Schanz J et al, J Clin Oncology 2012; 30:820']['81', 'MC1488', 'Appendix V:', 'RISK STATUS BASED ON VALIDATED CYTOGENETICS AND MOLECULAR ABNORMALITIES\u00b9', 'RISK STATUS', 'CYTOGENETICS', 'MOLECULAR ABNORMALITIES', 'Better-risk', 'inv(16)', '2,3 or t(16;16)\u00b2', 'Normal cytogenetics:', 't(8;21)\u00b2', 'NPM1 mutation in the absence of FLT3-ITD', 't(15;17)', 'or isolated biallelic CEBPA mutation', 'Intermediate-risk', 'Normal cytogenetics', 't(8;21), inv(16), t(16;16)', '+8 alone', 'with c-KIT 5 mutation', 't(9;11)', 'Other non-defined', 'Poor-risk', 'Complex (>3 clonal chromosomal abnormalities)', 'Normal cytogenetics:', 'Monosomal karyotype', 'with FLT3-ITD mutation 6', '-5, 5q-, -7, 7q-', '11q23 - non t(9;11)', 'inv(3), t(3;3)', 't(6;9)', 't(9;22) 4', '1', 'The molecular abnormalities included in this table reflect those for which validated assays are available in standardized commercial laboratories. Given the rapidly', 'evolving field, risk stratification should be modified based on continuous evaluation of research data. Other novel genetic mutations have been identified that may have', 'prognostic significance.', '2 Other cytogenetic abnormalities in addition to these findings do not alter better risk status.', '3 Paschka P, Du J, Schlenk RF, et al. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML study group', '(AMLSG). Blood 2013;121:170-177.', '4 For Philadelphia+ AML t(9;22), manage as myeloid blast crisis in CML, with addition of tyrosine kinase inhibitors.', '5 Emerging data indicate that the presence of c-KIT mutations in patients with t(8;21), and to a lesser extent inv(16), confers a higher risk of relapse. These patients', 'should be considered for clinical trials, if available.', '6FLT3-ITD mutations are considered to confer a significantly poorer outcome in patients with normal karyotype, and these patients should be considered', 'for', 'clinical', 'trials', 'where available. There is controversy as to whether FLT3-TKD mutations carry an equally poor prognosis.', 'Version 2.2014, 03/28/2014. National Comprehensive Cancer Network, Inc. 2014.']\n\n###\n\n", "completion": "END"}